Integrated genomic and clinical database for cancer biomarker discovery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an investigator-initiated observational study at Samsung Medical Center aimed at creating a comprehensive database that links genomic, molecular, and clinical data from adults with cancer or those undergoing routine screening. The project collects tissue and blood samples obtained during standard care, along with previously collected specimens from the biobank, and links their molecular results with cancer diagnoses, treatments, responses, and outcomes. Genetic, molecular, and protein analyses will be performed and integrated with clinical information to support precision oncology and predictive modeling. Patient-derived organoids and immune cells may be used to explore drug response in a research setting. The study does not assign interventions but seeks to enable future biomarker validation and personalized treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 19 years or older.
* Patients diagnosed with or suspected of having cancer who are scheduled to undergo tissue collection for diagnostic, surgical, or therapeutic purposes.
* Individuals undergoing routine health screening at Samsung Medical Center who voluntarily provide informed consent to participate in the study.
* Patients who voluntarily provide informed consent to participate in the study, including consent for genetic analysis.
* Individuals whose previously collected tissue or blood specimens are available through the Samsung Medical Center Biobank, including specimens from patients with gastric, colorectal, liver, pancreatic, biliary tract, lung, breast, esophageal, hematologic, or kidney cancers, in accordance with applicable consent and ethical requirements.
* Participants previously enrolled in an approved research study (IRB File No. 2020-02-015) whose stored biospecimens remain within the approved retention period and for whom consent for secondary use has been obtained. Additional consent is not required for these specimens when permitted under the approved protocol.

Exclusion Criteria:

* Individuals considered unsuitable for study participation at the investigator's discretion.
* Participants who withdraw their consent after enrollment.
* Participants from previously approved research studies whose biospecimen retention period has expired or who did not consent to secondary use of their specimens.

Where it's running

• Samsung Medical Center
  Seoul, Gang-Nam, South Korea Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• MRG007 (ARR-217) treatment for advanced solid tumors

  This trial will test MRG007 (ARR-217), an antibody-drug conjugate that targets CDH17, in adults with unresectable locally advanced or metastatic solid tumors who have exhausted standard therapies.

  Recruiting at 21 sites Phase 1 ArriVent BioPharma, Inc. · Los Angeles, California and 20 other locations · NCT07066657

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

• AI-assisted non-contrast CT for detecting multiple cancers

  This study is testing whether an AI tool can help find different types of cancer earlier in healthy people getting routine check-ups.

  Recruiting Changhai Hospital · Shanghai, Shanghai Municipality · NCT06632886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.